The Indian regulators woke up only after US Food and Drug Administration authorities were critical of the medicines made in India for the US markets, and restricted supplies from one of the biggest producers of generic drugs. It is certain that these units are supplying medicines to gullible Indians and also compromising their health and safety. Shockingly, the drugs controller states that if India were to follow international standards, then many facilities should be shut down. Our claims of being "world class" should be redefined as "India class". The New York Times in a recent article has drawn attention to this serious loss of credibility for Indian generic drugs, which account for a significant share in the US and other world markets. Our reputation is also at stake because India supplies the much-needed generic drugs at competitive prices to Africa, Asia and South America as well.
Letters can be mailed, faxed or e-mailed to:
The Editor, Business Standard
Nehru House, 4 Bahadur Shah Zafar Marg
New Delhi 110 002
Fax: (011) 23720201
E-mail: letters@bsmail.in
All letters must have a postal address and telephone number
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
